Barcelona, March 2, 2026 – Today, the prominent Spanish newspaper La Vanguardia published a featured article on Chemotargets, highlighting the company’s 20-year legacy as a pioneer in designing drugs through computational science.
The article, titled “Chemotargets: 20 Years Designing Drugs with Computational Science” coincides with the opening day of 4YFN at Mobile World Congress (MWC) Barcelona, where Chemotargets is currently showcasing its latest innovations at the Catalonia Health Innovation Ecosystem Pavilion.
Being chosen as one of only 16 health-sector startups for the pavilion—supported by Biocat, ACCIÓ, the Department of Health, and the Barcelona City Council—underscores our position at the forefront of the digital health revolution.
The article explores Chemotargets’ journey from its origins to becoming a global reference in AI-driven drug discovery and translational safety. Over twenty years, we have evolved into a “Deep Tech” powerhouse, utilizing advanced Machine Learning to bridge the gap between complex data and life-saving therapies.
By utilizing advanced Machine Learning to navigate complex biomedical data, Chemotargets’ leadership has successfully positioned the company as a trusted partner for global pharmaceutical giants and regulatory bodies alike. This strategic direction has ensured that the company remains at the cutting edge of the digital health revolution, transforming how life-saving therapies are identified and developed.
Two Decades of Scientific Leadership
The feature explores Chemotargets’ evolution from a research-driven spin-off to a global reference in the biotech industry. Over the past two decades, the company has remained at the forefront of the “Deep Tech” revolution, utilizing AI and Machine Learning to bridge the gap between complex data and the development of safe, life-saving therapies.
“Having our journey recognized by a publication as prestigious as La Vanguardia is an honor that reflects the hard work and scientific vision of our entire team,” said the Chemotargets management team. “As we celebrate our 20th anniversary, we remain more committed than ever to accelerating drug discovery and improving patient safety through cutting-edge technology.”
The publication comes at a pivotal moment as Chemotargets engages with global investors and tech leaders at 4YFN. We invite our partners and the scientific community to read the full feature and join us this week in Barcelona to discuss the next 20 years of innovation.
Read the full article here: La Vanguardia: Chemotargets – 20 años diseñando fármacos con ciencia computacional
